levetiracetam / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 185 Diseases   81 Trials   81 Trials   6476 News 


«12...678910111213141516...8182»
  • ||||||||||  levetiracetam / Generic mfg.
    Observational data, Journal:  Association of Prenatal Exposure to Antiseizure Medications With Creative and Executive Function at Age 4.5 Years. (Pubmed Central) -  May 29, 2024   
    P=N/A
    Secondary analyses revealed fetal exposure-dependent effects for executive function in children of WWE (7.0 [2.9-11.2], p = 0.001), which are most marked for levetiracetam (12.9 [4.2-21.6], p = 0.004). Our findings suggest that even for relatively safe ASMs, dosing needs to be adjusted to concentrations that prevent seizures, but balance risks to the fetus that high concentrations may pose.
  • ||||||||||  levetiracetam / Generic mfg., carbamazepine / Generic mfg.
    Journal, HEOR, Cost-effectiveness, Cost effectiveness:  Cost-effectiveness analysis of HLA-B*15:02 screening before treatment of epilepsy in Indonesia. (Pubmed Central) -  May 26, 2024   
    This suggests that therapy revision could be expedited. Calculation of the cost-effectiveness of lifetime epilepsy therapy in this study found that the initial screening strategy with the HLA-B*15:02 test was the most cost-effective.
  • ||||||||||  padsevonil (UCB0942) / UCB, levetiracetam / Generic mfg., brivaracetam / Generic mfg.
    Review, Journal:  Development of SV2A Ligands for Epilepsy Treatment: A Review of Levetiracetam, Brivaracetam, and Padsevonil. (Pubmed Central) -  May 25, 2024   
    Even so, the next-generation SV2A ligands against epilepsy based on the structure of LEV have achieved clinical success. This review highlights the research and development (R&D) process of LEV and its analogs, brivaracetam and padsevonil, to provide ideas and experience for the R&D of novel ASMs.
  • ||||||||||  levetiracetam / Generic mfg., topiramate / Generic mfg., carbamazepine / Generic mfg.
    Journal:  Correlation of drug dose estimated from national prescription registers with mean blood level of antiseizure medication in pregnancy. (Pubmed Central) -  May 24, 2024   
    Levetiracetam and phenytoin are comparable in efficacy in terms of achieving clinical seizure control in children with acute encephalitis syndrome, although levetiracetam group demonstrated fewer adverse effects. Dose of antiseizure medication estimated from prescription fills was a good proxy for blood levels and thus for biological exposure in pregnancy, suggesting that administrative prescription fill records may be a valuable resource for estimating exposure to antiseizure medication in pregnancy.
  • ||||||||||  Review, Journal:  Presynaptic antiseizure medications - basic mechanisms and clues for their rational combinations. (Pubmed Central) -  May 22, 2024   
    Dose of antiseizure medication estimated from prescription fills was a good proxy for blood levels and thus for biological exposure in pregnancy, suggesting that administrative prescription fill records may be a valuable resource for estimating exposure to antiseizure medication in pregnancy. Of them, levetiracetam and brivaracetam show a high affinity to the synaptic vesicle protein type 2
  • ||||||||||  phenobarbital / Generic mfg., levetiracetam / Generic mfg.
    Journal:  Short subcutaneous infusions for symptom control in palliative medicine. (Pubmed Central) -  May 17, 2024   
    SSCIs appear to be a promising additional option for administering medicines that are too irritant or large in volume for SC bolus injection. For medications with longer half-lives (eg, phenobarbital, valproate, levetiracetam), SSCI loading doses would be expected to achieve steady state and, thus, symptom relief, sooner than CSCIs alone.
  • ||||||||||  Fycompa (perampanel) / Eisai, Catalyst Pharma
    Journal, Monotherapy:  Optimizing perampanel monotherapy for surgically resected brain tumors. (Pubmed Central) -  May 17, 2024   
    PER monotherapy may be safe and effective for seizure treatment or prophylaxis in patients with brain tumor. Further large-scale clinical studies are warranted.
  • ||||||||||  aspirin / Generic mfg., levetiracetam / Generic mfg., oxcarbazepine / Generic mfg.
    Retrospective data, Journal:  Retrospective Analysis of Presymptomatic Treatment In Sturge-Weber Syndrome. (Pubmed Central) -  May 15, 2024   
    Presymptomatic treatment is a promising approach to children diagnosed with SWS prior to seizure onset. Further study is needed, including prospective drug trials, long-term neuropsychological outcome, and prospective EEG analysis to assess this approach and determine biomarkers for presymptomatic treatment.
  • ||||||||||  Fycompa (perampanel) / Eisai, Catalyst Pharma
    Journal, Combination therapy:  Effectiveness analysis of three-drug combination therapies for refractory focal epilepsy. (Pubmed Central) -  May 11, 2024   
    Further study is needed, including prospective drug trials, long-term neuropsychological outcome, and prospective EEG analysis to assess this approach and determine biomarkers for presymptomatic treatment. Among these triple regimens, lamotrigine (LTG)/valproic acid (VPA)/topiramate (TPM) was the most frequently prescribed (29.4%, n
  • ||||||||||  levetiracetam / Generic mfg., carbamazepine / Generic mfg.
    Journal:  Specific Birth Defects Following Antiseizure Medications Used By Pregnant Women With Epilepsy. (Pubmed Central) -  May 9, 2024   
    However, these medications were also associated with certain birth defects, including some not reported previously. We are among the first to examine the possible effects of levetiracetam use in pregnancy, though more research is needed to investigate this further.
  • ||||||||||  levetiracetam / Generic mfg.
    Evaluation of PET Radiotracers for Imaging Synaptic Density in Alzheimer (Exhibit Hall D - Science Pavilion (Convention Center); Screen 40; In-Person Only) -  May 8, 2024 - Abstract #SNMMI2024SNMMI_1194;    
    This work supports previous in vivo PET imaging studies, and reinforces the application of [18F]SynVesT-1 for synaptic density evaluation in patients suffering from AD. This data herein will guide our clinical research PET imaging programs and will continue to explore synaptic density via SV2A for imaging in AD and related dementias.
  • ||||||||||  progesterone / Generic mfg., levetiracetam / Generic mfg., carbamazepine / Generic mfg.
    Journal:  Relationship between depression and sex steroid hormone among women with epilepsy. (Pubmed Central) -  May 7, 2024   
    There was higher mean depression score, lower prolactin and higher testosterone level among cases compared to control. Furthermore, there was lower prolactin and higher testosterone level in Carbamazepine (CBZ) group compared to Levetiracetam (LEV) groups.
  • ||||||||||  levetiracetam / Generic mfg.
    Journal:  A rare case of lupus cerebritis presenting as ictal epileptic headache: A case report. (Pubmed Central) -  May 3, 2024   
    The patient was initiated on levetiracetam, which resulted in the resolution of both the epileptic discharges and the headaches. This case underscores the significance of considering ictal epileptic headache as a potential secondary cause for headaches, particularly in patients with underlying conditions that may predispose them to epilepsy, such as systemic lupus erythematosus.
  • ||||||||||  lorazepam / Generic mfg., levetiracetam / Generic mfg.
    Journal:  Bihemispheric Seizure Without Generalization. (Pubmed Central) -  Apr 26, 2024   
    This practice serves as a foundation for adjusting the drug treatment plan and offering more precise guidance for medication management during pregnancy. Clinical events did not recur after intravenous lorazepam (4
  • ||||||||||  Review, Journal:  Clinical approaches for poststroke seizure: a review. (Pubmed Central) -  Apr 25, 2024   
    Antiseizure drugs such as lamotrigine, carbamazepine, lacosamide, levetiracetam, phenytoin, and valproate may be administered. Poststroke seizures should be diagnosed systematically through history with differential diagnosis; in addition, classifying them as early or late seizures can help to determine treatment strategies.
  • ||||||||||  levetiracetam / Generic mfg.
    Trial completion, Enrollment change:  ILiAD: An Investigation of Levetiracetam in Alzheimer's Disease (clinicaltrials.gov) -  Apr 23, 2024   
    P2,  N=8, Completed, 
    Levetiracetam administered via IVP may be considered as a safe alternative method of administration in the acute care setting. Active, not recruiting --> Completed | N=30 --> 8
  • ||||||||||  levetiracetam / Generic mfg.
    Journal:  Effect of levetiracetam on DNA oxidation and glutathione content in a temporal lobe epilepsy model. (Pubmed Central) -  Apr 12, 2024   
    No significant differences in GSH levels were observed. LEV could induce changes in the hippocampus increasing DNA oxidation and GSSG levels under nonepileptic condition but not protecting against the mitochondrial dysfunction observed in TLE probably by mechanisms related to changes in chromatin structure, neuroinflammation and alterations in redox components.
  • ||||||||||  phenobarbital / Generic mfg.
    Journal:  Early life phenobarbital exposure dysregulates the hippocampal transcriptome. (Pubmed Central) -  Apr 12, 2024   
    These data are consistent with the existing literature showing developmental neurotoxicity associated with PB, but not LEV. The widespread change in gene expression after PB, which affected transcripts reflective of multiple cell types, may provide a link between acute drug administration and lasting drug toxicity.
  • ||||||||||  prednisone / Generic mfg., levetiracetam / Generic mfg.
    Enrollment open:  CAN-GT: rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan Disease (clinicaltrials.gov) -  Apr 11, 2024   
    P1/2,  N=24, Recruiting, 
    The widespread change in gene expression after PB, which affected transcripts reflective of multiple cell types, may provide a link between acute drug administration and lasting drug toxicity. Active, not recruiting --> Recruiting
  • ||||||||||  levetiracetam / Generic mfg.
    Trial completion date, Trial primary completion date:  BDE: Precision Medicine in the Treatment of Epilepsy (clinicaltrials.gov) -  Apr 11, 2024   
    P=N/A,  N=550, Recruiting, 
    Active, not recruiting --> Recruiting Trial completion date: Feb 2030 --> Dec 2031 | Trial primary completion date: Feb 2025 --> Dec 2026
  • ||||||||||  Xatmep (methotrexate oral solution) / Azurity Pharma, Nexlizet (bempedoic acid/ezetimibe) / Esperion Therap, Otsuka, Daiichi Sankyo
    Trial completion, Enrollment change:  Drug Concentrations in Breast Milk and Prediction of Blood Levels of the Breastfed Infants (clinicaltrials.gov) -  Apr 9, 2024   
    P=N/A,  N=39, Completed, 
    Trial completion date: Feb 2030 --> Dec 2031 | Trial primary completion date: Feb 2025 --> Dec 2026 Recruiting --> Completed | N=304 --> 39